Columbia has taken an equity stake in the antiviral therapeutics producer, co-founded by two of its faculty members.

RenBio, a US-based antiviral therapy developer, has raised $24m in a series A round and secured a licence for its lead candidate developed at Columbia University. Industrial conglomerate Ruentex Group led the series A round, while Columbia University secured an equity stake as part of the licence. RenBio is working on antibody therapeutics. Its Columbia-licensed…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.